U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.21%)
     
  • BTC-USD

    21,399.37
    +126.76 (+0.60%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CytomX Therapeutics Inc (NASDAQ: CTMX) announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC).

  • The CD71-directed conditionally activated antibody-drug conjugate (ADC) is being co-developed by CytomX and AbbVie Inc (NYSE: ABBV).

  • In the 16 efficacy, evaluable patients with sqNSCLC, the objective response rate (ORR) was 18.8%, including two confirmed partial responses (PRs) and one unconfirmed PR that was confirmed seven days after the data cutoff of October 29, 2021.

  • Two of these responses were ongoing, and the third had a response duration of 5.6 months. The disease control rate (DCR) was 87.5%.

  • In the 25 efficacy evaluable patients with HNSCC, there was one confirmed PR (ORR 4.0%) and a DCR of 56%, including one unconfirmed PR.

  • The safety profile was consistent with the previous observations, with no new safety signals identified.

  • The most common treatment-related adverse events (TRAEs) were anemia, infusion-related reactions, fatigue & nausea, and decreased neutrophil count.

  • Price Action: CTMX shares are down 23.4% at $4.94 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.